Abstract 4226
Background
CEA, CA19.9, cDNA and CTC have been reported as useful circulating markers in mCRC pts treated with chemotherapy (CT)-based regimen. We previously reported that CEA kinetic (threshold 0.05) was associated witht outcome [Iwanicki-Caron et al, J Clin Oncol 2008;26:3681-6]. We designed a prospective muticentric trial for CEA kinetic validation and to evaluate CA19.9, cDNA and CTC kinetics.
Methods
mCRC pts, PS 0-2, with CEA ≥ 5 µg/L or CA19.9 ≥ 30UI/mL, and who started a CT regimen were included. Plasma were collected taken from baseline (T0) to the fourth cycle for CEA and CA19.9 and at T0 and 6 weeks (W6) for cDNA and CTC kinetics. Cell-free DNA (cfDNA) was quantified by fluorimetric method, circulating tumour DNA (ctDNA) by Digital PCR and CTC (CTC+ vs CTC-) by ScreenCell(R) method. Primary endpoint was 3-months evaluation (control disease (CD) (response/stable) vs progressive disease (PD))) (RECIST 1.1) according to CEA kinetic. Secondary endpoints were progression-free survival (PFS) and overall survival (OS) according to baseline T0 median values (high vs low) of CEA, CA19.9, cfDNA, ctDNA, and CTC +/- and kinetics.
Results
A total of 200 mCRC pts were included with a median follow-up of 12 months (m) (range 1-41). Median CEA, CA19.9, cfDNA and ctDNA were 96 µg/L, 88 UI/mL, 24.2 ng/mL and 15.2% respectively. CtDNA was detected in 90% at T0 from the 95 KRAS/BRAF mutated tumours. A total of 54.7% were CTC+ at T0. CEA kinetic (≤0.05 threshold) was associated with response CD (90 vs 52%, p
Conclusions
This prospective study confirmed that CEA kinetic is clinically relevant to monitor CT in mCRC. Results also highlight that CA19.9, cfDNA and ctDNA are also associated with outcome.
Clinical trial identification
Protocol : 2009/170/HP Clinical trial number : NCT01212510
Legal entity responsible for the study
CHU Rouen
Funding
Amgen, Roche and Merck (pharma) Fondation Pierre Durand et Marie-Therese Chevalier
Disclosure
D. Sefrioui, P. Michel, F. Di Fiore: Industrial partnership with Merck, Amgen and Roche. All other authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract